The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. announced that extended follow-up data from its phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer will be presented at the American Urological Association’s annual meeting, AUA2026, in Washington, D.C.
The data release is anticipated to provide further insight into the efficacy and durability of the CAN-2409 immunotherapy approach for patients with localized prostate cancer, potentially shaping future treatment strategies. The results will be shared with a broad audience of urology experts and researchers during the highly regarded urological conference.